Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis


Disclosures: DML: Novartis speaker, Jazz Pharmaceutical advisory board. YC: Novartis advisory board and travel grant. NK: research grant and Honoria from Neovii. JF: research grant, speaker Honoria and travel support with MEDAC, NEOVII, NOVARTIS, RIEMSER;

Contributions: MR, YC and NK designed the study, LDW and DJE did statistics, NSK did data management, MR, YC, NK, DML analyzed the data, MR, CW, JS, MTVL, DB, AB, DN, AV, WB, RA, JF, LV, IYA, AN, XP, HE, PC, EH, PL, ST, AR and NK provided the patients, MR wrote the paper, all co-authors had opportunity to discuss results and approved the final manuscript.